ClinicalTrials.gg
CompletedNCT04072575Updated Apr 29, 2025Results posted

A Study of Paliperidone Palmitate 6-Month Formulation

A Phase 3 interventional study of PP6M injection Dose 1 and PP6M injection Dose 2 in Schizophrenia, sponsored by Janssen Research & Development, LLC. Completed at 30 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
178
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
58th of 115
178 · median 178
Started
2019
with 1 other
Phase 3
41 of 115
none open now
Registered
104th of 115
by date
Lead sponsor
12 of 115
Janssen Research & Development, LLC

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 58th largest by enrollment, is one of 2 that started in 2019, is one of 41 in phase 3, and was the 104th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The main purpose of this study is to assess the long-term safety and tolerability of paliperidone 6-month PP6M (Dose 1 or Dose 2 [milligram] mg eq.) and to provide access to PP6M in participants with schizophrenia completing the R092670PSY3015 study without relapse.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed the Double-blind Phase of Study R092670PSY3015 without relapse and continue to be willing to be treated with paliperidone palmitate 6 month injection (PP6M)
  • Must, in the opinion of the investigator, be able to continue treatment at the same dose level (moderate or higher dose) as used during the Double-blind Phase of Study R092670PSY3015 at the time of screening for this study
  • A woman of : a) Must have a negative pregnancy test on Day 1; b) Use consistent with local regulations. A man must agree that during the study and for a minimum 12 months after receiving the last dose of the study intervention: a) His female partner(s) will use highly effective method pf contraception
  • Sign an form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study; and must be able to provide his or her own consent (that is, consent cannot be provided by a legal representative of the participant)
  • In the opinion of the investigator, the patient would be able to participate for the duration of this study

Exclusion criteria

Exclusion Criteria:

  • Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
  • Completed R092670PSY3015 while presenting adverse events deemed by the investigator, and which may interfere with safety and well-being of the participant
  • If a man, has plans to father a child while enrolled in this study or within 12 months after the last dose of study intervention. Must not, if a woman, have plans to become pregnant while enrolled in this study or within 12 months after the last dose of study intervention
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
178 participants (actual)

Study arms

  • Experimental
    Paliperidone Palmitate 6 month(PP6M)

    Participants who enter the this open-label extension study immediately after completing Double-blind Phase Study R092670PSY3015 (previous study) will receive Paliperidone Palmitate 6 month (PP6M) intramuscular (IM) injections, dose will be selected based on the unblinded dose level ("moderate" or "higher") that the participant received during previous study. Participants in the "moderate" dose level will receive PP6M Dose 1 and "higher" dose level will receive PP6M Dose 2 during the open-label extension. The PP6M dose level may be adjusted (to Dose 1 or Dose 2) for every 6 month at Visits 3, 5, and 7, based on clinical judgment. Participants who enter this open-label extension study later (up to 3 months after they complete previous study) and were on a moderate or higher dose of PP3M (350 or 525 mg eq.) or PP1M (100 or 150 mg eq.) will receive initial dose of PP6M IM injection (Dose 1 or Dose 2) for every 6 months.

    Drug: PP6M injection Dose 1 · Drug: PP6M injection Dose 2

Interventions

  • Participants will receive Dose 1 PP6M intramuscular (IM) injection at Visit 1 (Day) then once every 6 month up to 24 months.

    Also known as: R092670

  • Participants will receive Dose 2 PP6M IM injection at Visit 1 (Day) then once every 6 month up to 24 months.

    Also known as: R092670

06

What researchers measure

Primary outcomes

  1. Number of Participants With Relapse

    Number of participants with relapse were reported. Relapse is defined as one or more of the following: a) Psychiatric hospitalization for schizophrenia (involuntary or voluntary admission to a psychiatric hospital for decompensation of the participant's schizophrenic symptoms); b) Emergency Department/Room/Ward visit due to a worsening of the participant's symptoms of schizophrenia, but a psychiatric hospitalization does not occur; c) The participant inflicts deliberate self-injury or exhibits violent behaviour resulting in suicide, clinically significant injury to him/herself or another person, or significant property damage; d) The participant has suicidal or homicidal ideation and aggressive behaviour that is clinically significant (in frequency and severity) in the investigator's judgment.

    Time frame: Up to Day 730

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs are those events if they started after administration of the first dose and until 183 days after the last dose of study medication.

    Time frame: Up to Day 730

Secondary outcomes

  1. Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale Score

    Change from baseline in CGI-S scale score was reported. CGI-S is defined as clinician-rated scale that assesses the severity of mental illness on a scale of 0 to 7. Considering total clinical experience, a participant was assessed on severity of mental illness at the time of rating according to:1: normal, not at all ill; 2: borderline mentally ill; 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill participants. A higher score implies a more severe condition.

    Time frame: Baseline up to Day 730

  2. Change From Baseline in Personal and Social Performance (PSP) Scale Score

    Change from baseline in PSP scale score was reported. The PSP scale assesses degree of a participant's dysfunction within 4 domains of behavior: 1) socially useful activities, 2) personal and social relationships, 3) self-care, and 4) disturbing and aggressive behavior. Each domain was assessed on a 6-point scale, from 1 (absent) to 6 (very severe) (1 = absent, 2 = mild, 3 = manifest, 4 = marked, 5 = severe, and 6 = very severe). PSP total score was calculated as sum of all the domain scores and ranges from 1 to 100. Participants with score of 71 to 100 had mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision. Higher score indicates better performance.

    Time frame: Baseline up to Day 730

  3. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score

    Change from baseline in PANSS total score were reported. The neuropsychiatric symptoms of schizophrenia were assessed using the 30-item PANSS scale, which provides a total score (sum of the scores for all 30 items) and scores for 3 subscales: the 7-item positive-symptom (P) subscale, the 7-item negative-symptom (N) subscale, and the 16-item general-psychopathology symptom (G) subscale. Each item is rated on a scale of 1 (absent) to 7 (extreme). The PANSS total score ranges from 30 (absent disease)-210 (more severe neuropsychiatric symptoms of schizophrenia).

    Time frame: Baseline up to Day 730

07

Results

Posted May 31, 2023
Limitations and caveats
The sponsor identified that the study did not include a control arm reference group. The coronavirus disease-2019 (COVID-19) pandemic placed some restrictions on study face-to-face visits.

Participant flow

Participant flow — Overall Study
MilestoneTotal Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq.
Started178
Completed154
Not completed24
Withdrew: Physician decision1
Withdrew: Adverse event7
Withdrew: Withdrawal by subject14
Withdrew: Other2

Outcome measures

PrimaryNumber of Participants With Relapse

Number of participants with relapse were reported. Relapse is defined as one or more of the following: a) Psychiatric hospitalization for schizophrenia (involuntary or voluntary admission to a psychiatric hospital for decompensation of the participant's schizophrenic symptoms); b) Emergency Department/Room/Ward visit due to a worsening of the participant's symptoms of schizophrenia, but a psychiatric hospitalization does not occur; c) The participant inflicts deliberate self-injury or exhibits violent behaviour resulting in suicide, clinically significant injury to him/herself or another person, or significant property damage; d) The participant has suicidal or homicidal ideation and aggressive behaviour that is clinically significant (in frequency and severity) in the investigator's judgment.

Time frame:
Up to Day 730
Reported as:
Count of participants · Participants
Number of Participants With Relapse
ParticipantsTotal Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq.
Number of Participants With Relapse7
PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs are those events if they started after administration of the first dose and until 183 days after the last dose of study medication.

Time frame:
Up to Day 730
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsTotal Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq.
Number of Participants With Treatment-emergent Adverse Events (TEAEs)111
SecondaryChange From Baseline in Clinical Global Impression-Severity (CGI-S) Scale Score

Change from baseline in CGI-S scale score was reported. CGI-S is defined as clinician-rated scale that assesses the severity of mental illness on a scale of 0 to 7. Considering total clinical experience, a participant was assessed on severity of mental illness at the time of rating according to:1: normal, not at all ill; 2: borderline mentally ill; 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill participants. A higher score implies a more severe condition.

Time frame:
Baseline up to Day 730
Reported as:
Mean · Units on a scale
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale Score
Units on a scaleTotal Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq.
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Scale Score0.0 ± 0.51
SecondaryChange From Baseline in Personal and Social Performance (PSP) Scale Score

Change from baseline in PSP scale score was reported. The PSP scale assesses degree of a participant's dysfunction within 4 domains of behavior: 1) socially useful activities, 2) personal and social relationships, 3) self-care, and 4) disturbing and aggressive behavior. Each domain was assessed on a 6-point scale, from 1 (absent) to 6 (very severe) (1 = absent, 2 = mild, 3 = manifest, 4 = marked, 5 = severe, and 6 = very severe). PSP total score was calculated as sum of all the domain scores and ranges from 1 to 100. Participants with score of 71 to 100 had mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision. Higher score indicates better performance.

Time frame:
Baseline up to Day 730
Reported as:
Mean · Units on a scale
Change From Baseline in Personal and Social Performance (PSP) Scale Score
Units on a scaleTotal Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq.
Change From Baseline in Personal and Social Performance (PSP) Scale Score0.5 ± 7.47
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score

Change from baseline in PANSS total score were reported. The neuropsychiatric symptoms of schizophrenia were assessed using the 30-item PANSS scale, which provides a total score (sum of the scores for all 30 items) and scores for 3 subscales: the 7-item positive-symptom (P) subscale, the 7-item negative-symptom (N) subscale, and the 16-item general-psychopathology symptom (G) subscale. Each item is rated on a scale of 1 (absent) to 7 (extreme). The PANSS total score ranges from 30 (absent disease)-210 (more severe neuropsychiatric symptoms of schizophrenia).

Time frame:
Baseline up to Day 730
Reported as:
Mean · Units on scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score
Units on scaleTotal Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq.
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score0.7 ± 8.22

Adverse events

Collected over Up to Day 730. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq.0/178 (0%)8/178 (4.5%)68/178 (38.2%)
Most frequent serious events
Most frequent serious events
EventTotal Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq.
SchizophreniaPsychiatric disorders4/178
Colon CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/178
Metastases to PeritoneumNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/178
Hallucination, AuditoryPsychiatric disorders1/178
Psychiatric SymptomPsychiatric disorders1/178
Nephrotic SyndromeRenal and urinary disorders1/178
Most frequent other events
Most frequent other events
EventTotal Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq.
HeadacheNervous system disorders24/178
Blood Prolactin IncreasedInvestigations19/178
HyperprolactinaemiaEndocrine disorders13/178
DiarrhoeaGastrointestinal disorders11/178
NasopharyngitisInfections and infestations9/178
Weight IncreasedInvestigations9/178

Baseline characteristics

Age, Continuous
Age, Continuous(years)Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq.
Mean40.4 ± 10.76
Sex: Female, Male
Sex: Female, Male(Participants)Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq.
Female52
Male126
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq.
Hispanic or Latino48
Not Hispanic or Latino130
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq.
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American0
White176
More than one race0
Unknown or Not Reported0
08

Study locations

30 sites
  • Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales
    Ciudad Autónoma De Buenos Aires, C1133AAH, Argentina
  • CEN Consultorios Especializados en Neurociencias
    Cordoba, X5004FJF, Argentina
  • Sanatorio Prof. Leon S. Morra
    Cordoba, X5009BIN, Argentina
  • INSA Instituto de Neurociencias San Agustín
    La Plata, 1900, Argentina
  • Clinica Privada de Salud Mental Santa Teresa de Ávila
    La Plata, B1904ADM, Argentina
  • C I A P Centro de investigacion y Asistencia en Psiquiatria
    Rosario, 2000, Argentina
  • Queen Mary Hospital
    Hong Kong, Hong Kong
  • Dipartimento di Salute Mentale
    Lecce, 73100, Italy
  • Seconda Universita degli Studi di Napoli - Azienda Ospedaliera Universitaria
    Napoli, 80138, Italy
  • Universita degli Studi di Roma 'La Sapienza' - Azienda Ospedaliera Sant Andrea
    Roma, 00189, Italy
  • Mlynowamed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk
    Bialystok, 15-404, Poland
  • Zespol Opieki Zdrowotnej w Chelmnie
    Chelmno, 86-200, Poland
  • Centrum Badan Klinicznych PI House sp z o o
    Gdansk, 80 546, Poland
  • Specjalistyczna Praktyka Lekarska Piotr Zalitacz
    Gorlice, 38-300, Poland
  • Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS
    Leszno, 64-100, Poland
  • Centrum Medyczne Luxmed Sp z o o
    Lublin, 20 109, Poland
  • Poradnia Zdrowia Psychicznego 'Syntonia' w Pruszczu Gdanskim
    Pruszcz Gdanski, 83-000, Poland
  • Sverdlovsk Regional Clinical Psychiatric Hospital
    Ekaterinburg, Russian Federation
  • Nizny Novgorod clinical psychiatric hospital 1
    Nizny Novgorod, 603155, Russian Federation
  • SHI 'Saratov City Clinical Hospital 2 n.a V.I. Razumovsky
    Saratov, 410028, Russian Federation
  • Saratov Regional Psychiatric hospital named after St. Sofia
    Saratov, 410060, Russian Federation
  • Research Institute of Mental Health
    Tomsk, 634014, Russian Federation
  • MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association
    Glevakha, 8630, Ukraine
  • Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'
    Kharkiv, 61068, Ukraine
  • CNPE'Kherson Regional Institution of Mental Care'of Kherson Regional Council
    Kherson, 73488, Ukraine
  • Mnpe of Lviv Regional Council 'Lviv Regional Clinical Psycho-Neurological Dispensary'
    Lviv, 79000, Ukraine
  • CNCE of the Lviv Regional Council 'Lviv Regional Clinical Psychiatric Hospital'
    Lviv, 79021, Ukraine
  • CNCE Odesa regional psychiatric hospital #2 Odesa regional council
    Oleksandrivka, 67513, Ukraine
  • CNCE 'Cherkasy Regional Psychiatric Hospital of Cherkasy Regional Council'
    Smila, 20708, Ukraine
  • CNCE 'Vinnytsya RC Psychoneurological Hospital n.a. O.I. Yushchenko Vinnytsya RC'
    Vinnytsia, 21005, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in May 2022, 31 months.

Results were first posted in May 2023, 1 year after primary completion.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's 31 months is close to that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2019
First posted
Aug 28, 2019
StartActual
Sep 19, 2019
Primary completionActual
May 3, 2022
CompletionActual
May 3, 2022
Results first posted
May 31, 2023
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04072575
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
Sep 19, 2019
Primary completion
May 3, 2022
Completion
May 3, 2022
Results posted
May 31, 2023
Last update
Apr 29, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion